The role of immune semaphorins in cancer progression

Experimental Cell Research

Volumn 319, Issue 11, 2013, Pages 1635-1643

  Eissler, Nina ^a   Rolny, Charlotte ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Angiogenesis; Dendritic cells; Immune semaphorins; Metastatic dissemination; Neuropilin1; NK cells; T cells; Tumor associated macrophages; Tumor growth; Vessel functionality

Indexed keywords

CD72 ANTIGEN; NEUROPILIN 1; NEUROPILIN 2; PLEXIN; SCATTER FACTOR; SEMAPHORIN; SEMAPHORIN 3A; SEMAPHORIN 3F; TOLL LIKE RECEPTOR; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; BINDING SITE; BREAST CANCER; CANCER GROWTH; COLON CANCER; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOFT TISSUE CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANGIOGENESIS; DENDRITIC CELLS; IMMUNE SEMAPHORINS; METASTATIC DISSEMINATION; NEUROPILIN1; NK CELLS; T-CELLS; TUMOR ASSOCIATED MACROPHAGES; TUMOR GROWTH; VESSEL FUNCTIONALITY;

ANIMALS; DISEASE PROGRESSION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SEMAPHORINS; SIGNAL TRANSDUCTION;

EID: 84879600896     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.04.016     Document Type: Review

References (70)

1. M. Rehman, L. Tamagnone, Semaphorins in cancer: Biological mechanisms and therapeutic approaches, Semin. Cell Dev. Biol (2012).
2. Schwarz Q., Ruhrberg C. Neuropilin, you gotta let me know: should I stay or should I go?. Cell adhes. & migration 2010, 4:61-66.
3. Tamagnone L., Artigiani S., Chen H., He Z., Ming G.I., Song H., Chedotal A., Winberg M.L., Goodman C.S., Poo M., Tessier-Lavigne M., Comoglio P.M. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999, 99:71-80.
4. Gu C., Yoshida Y., Livet J., Reimert D.V., Mann F., Merte J., Henderson C.E., Jessell T.M., Kolodkin A.L., Ginty D.D. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 2005, 307:265-268.
5. Suzuki K., Kumanogoh A., Kikutani H. Semaphorins and their receptors in immune cell interactions. Nat. Immunol. 2008, 9:17-23.
6. Takamatsu H., Okuno T., Kumanogoh A. Regulation of immune cell responses by semaphorins and their receptors. Cell Mol. Immunol. 2010, 7:83-88.
7. Basile J.R., Castilho R.M., Williams V.P., Gutkind J.S. Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:9017-9022.
8. Kato S., Kubota K., Shimamura T., Shinohara Y., Kobayashi N., Watanabe S., Yoneda M., Inamori M., Nakamura F., Ishiguro H., Nakaigawa N., Nagashima Y., Taguri M., Kubota Y., Goshima Y., Morita S., Endo I., Maeda S., Nakajima A., Nakagama H. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. Cancer Sci. 2011, 102:2029-2037.
9. Sierra J.R., Corso S., Caione L., Cepero V., Conrotto P., Cignetti A., Piacibello W., Kumanogoh A., Kikutani H., Comoglio P.M., Tamagnone L., Giordano S. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J. Exp. Med. 2008, 205:1673-1685.
10. Dorfman D.M., Shahsafaei A., Nadler L.M., Freeman G.J. The leukocyte semaphorin CD100 is expressed in most T-cell, but few B-cell, non-Hodgkin's lymphomas. Am. J. Pathol. 1998, 153:255-262.
11. Staton C.A., Shaw L.A., Valluru M., Hoh L., Koay I., Cross S.S., Reed M.W., Brown N.J. Expression of class 3 semaphorins and their receptors in human breast neoplasia. Histopathology 2011, 59:274-282.
12. Barresi V., Vitarelli E., Cerasoli S. Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density. Virchows Arch.: int. J. Pathol. 2009, 454:563-571.
13. Yoshikawa Y., Sato A., Tsujimura T., Morinaga T., Fukuoka K., Yamada S., Murakami A., Kondo N., Matsumoto S., Okumura Y., Tanaka F., Hasegawa S., Hashimoto-Tamaoki T., Nakano T. Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells. Int. J. Oncol. 2011, 39:1365-1374.
14. Muller M.W., Giese N.A., Swiercz J.M., Ceyhan G.O., Esposito I., Hinz U., Buchler P., Giese T., Buchler M.W., Offermanns S., Friess H. Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer,. Int. J. cancer Journal international du cancer 2007, 121:2421-2433.
15. Glinka Y., Mohammed N., Subramaniam V., Jothy S., Prud'homme G.J. Neuropilin-1 is expressed by breast cancer stem-like cells and is linked to NF-kappaB activation and tumor sphere formation. Biochem. Biophys. Res. Commun. 2012, 425:775-780.
16. Catalano A., Lazzarini R., Di Nuzzo S., Orciari S., Procopio A. The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells. Cancer. Res. 2009, 69:1485-1493.
17. Meyerson H.J., Blidaru G., Edinger A., Osei E., Schweitzer K., Fu P., Ho L. NRP-1/CD304 expression in acute leukemia: a potential marker for minimal residual disease detection in precursor B-cell acute lymphoblastic leukemia. Am. J. Clin. Pathol. 2012, 137:39-50.
18. Bachelder R.E., Lipscomb E.A., Lin X., Wendt M.A., Chadborn N.H., Eickholt B.J., Mercurio A.M. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer. Res. 2003, 63:5230-5233.
19. Jubb A.M., Strickland L.A., Liu S.D., Mak J., Schmidt M., Koeppen H. Neuropilin-1 expression in cancer and development. J. Pathol. 2012, 226:50-60.
20. Berge M., Allanic D., Bonnin P., de Montrion C., Richard J., Suc M., Boivin J.F., Contreres J.O., Lockhart B.P., Pocard M., Levy B.I., Tucker G.C., Tobelem G., Merkulova-Rainon T. Neuropilin-1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodelling. J. Hepatol. 2011, 55:866-875.
21. Bielenberg D.R., Pettaway C.A., Takashima S., Klagsbrun M. Neuropilins in neoplasms: expression, regulation, and function. Exp. Cell. Res. 2006, 312:584-593.
22. Jubb A.M., Sa S.M., Ratti N., Strickland L.A., Schmidt M., Callahan C.A., Koeppen H. Neuropilin-2 expression in cancer. Histopathology 2012, 61:340-349.
23. Roodink I., Kats G., van Kempen L., Grunberg M., Maass C., Verrijp K., Raats J., Leenders W. Semaphorin 3E expression correlates inversely with Plexin D1 during tumor progression. Am. J. Pathol. 2008, 173:1873-1881.
24. Roodink I., Verrijp K., Raats J., Leenders W.P. Plexin D1 is ubiquitously expressed on tumor vessels and tumor cells in solid malignancies. BMC cancer 2009, 9:297.
25. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer cell 2009, 15:220-231.
26. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer cell 2009, 15:232-239.
27. Kessler O., Shraga-Heled N., Lange T., Gutmann-Raviv N., Sabo E., Baruch L., Machluf M., Neufeld G. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer. Res. 2004, 64:1008-1015.
28. Casazza A., Kigel B., Maione F., Capparuccia L., Kessler O., Giraudo E., Mazzone M., Neufeld G., Tamagnone L. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. EMBO mol. med. 2012, 4:234-250.
29. Casazza A., Finisguerra V., Capparuccia L., Camperi A., Swiercz J.M., Rizzolio S., Rolny C., Christensen C., Bertotti A., Sarotto I., Risio M., Trusolino L., Weitz J., Schneider M., Mazzone M., Comoglio P.M., Tamagnone L. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J. Clin. Invest. 2010, 120:2684-2698.
30. Casazza A., Fu X., Johansson I., Capparuccia L., Andersson F., Giustacchini A., Squadrito M.L., Venneri M.A., Mazzone M., Larsson E., Carmeliet P., De Palma M., Naldini L., Tamagnone L., Rolny C. Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. Arterioscler. Thromb. Vasc. Biol. 2011, 31:741-749.
31. Maione F., Molla F., Meda C., Latini R., Zentilin L., Giacca M., Seano G., Serini G., Bussolino F., Giraudo E. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin. Invest. 2009, 119:3356-3372.
32. Maione F., Capano S., Regano D., Zentilin L., Giacca M., Casanovas O., Bussolino F., Serini G., Giraudo E. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J. Clin. Invest. 2012, 122:1832-1848.
33. Pan Q., Chanthery Y., Liang W.C., Stawicki S., Mak J., Rathore N., Tong R.K., Kowalski J., Yee S.F., Pacheco G., Ross S., Cheng Z., Le Couter J., Plowman G., Peale F., Koch A.W., Wu Y., Bagri A., Tessier-Lavigne M., Watts R.J. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer cell 2007, 11:53-67.
34. Cao Y., Wang L., Nandy D., Zhang Y., Basu A., Radisky D., Mukhopadhyay D. Neuropilin-1 upholds dedifferentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes. Cancer. Res. 2008, 68:8667-8672.
35. Rizzolio S., Rabinowicz N., Rainero E., Lanzetti L., Serini G., Norman J., Neufeld G., Tamagnone L. Neuropilin-1-Dependent Regulation of EGF-Receptor Signaling. Cancer. Res. 2012, 72:5801-5811.
36. Mak P., Leav I., Pursell B., Bae D., Yang X., Taglienti C.A., Gouvin L.M., Sharma V.M., Mercurio A.M. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer cell 2010, l17:319-332.
37. Jurisic G., Maby-El Hajjami H., Karaman S., Ochsenbein A.M., Alitalo A., Siddiqui S.S., Ochoa Pereira C., Petrova T.V., Detmar M. An unexpected role of semaphorin3a-neuropilin-1 signaling in lymphatic vessel maturation and valve formation. Circ. Res. 2012, 111:426-436.
38. Bouvree K., Brunet I., Del Toro R., Gordon E., Prahst C., Cristofaro B., Mathivet T., Xu Y., Soueid J., Fortuna V., Miura N., Aigrot M.S., Maden C.H., Ruhrberg C., Thomas J.L., Eichmann A. Semaphorin3A, Neuropilin-1, and PlexinA1 are required for lymphatic valve formation. Circ. Res. 2012, 111:437-445.
39. Xin Y., Li J., Wu J., Kinard R., Weekes C.D., Patnaik A., Lorusso P., Brachmann R., Tong R.K., Yan Y., Watts R., Bai S., Hegde P.S. Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors. Clin. Cancer res.: an official J. Am. Assoc. Cancer Res. 2012, 18:6040-6048.
40. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., Autiero M., Wyns S., Plaisance S., Moons L., van Rooijen N., Giacca M., Stassen J.M., Dewerchin M., Collen D., Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
41. Rolny C., Mazzone M., Tugues S., Laoui D., Johansson I., Coulon C., Squadrito M.L., Segura I., Li X., Knevels E., Costa S., Vinckier S., Dresselaer T., Akerud P., De Mol M., Salomaki H., Phillipson M., Wyns S., Larsson E., Buysschaert I., Botling J., Himmelreich U., Van Ginderachter J.A., De Palma M., Dewerchin M., Claesson-Welsh L., Carmeliet P. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer cell 2011, 19:31-44.
42. Zhou H., Yang Y.H., Binmadi N.O., Proia P., Basile J.R. The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma. Exp. Cell Res. 2012, 318:1685-1698.
43. Yang Y.H., Zhou H., Binmadi N.O., Proia P., Basile J.R. Plexin-B1 activates NF-kappaB and IL-8 to promote a pro-angiogenic response in endothelial cells. PLoS One 2011, 6:e25826.
44. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer cell 2012, 21:309-322.
45. Rolny C., Capparuccia L., Casazza A., Mazzone M., Vallario A., Cignetti A., Medico E., Carmeliet P., Comoglio P.M., Tamagnone L. The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J. Exp. Med. 2008, 205:1155-1171.
46. De Palma M., Venneri M.A., Galli R., Sergi Sergi L., Politi L.S., Sampaolesi M., Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer cell 2005, 8:211-226.
47. De Palma M., Venneri M.A., Roca C., Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 2003, 9:789-795.
48. Pucci F., Venneri M.A., Biziato D., Nonis A., Moi D., Sica A., Di Serio C., Naldini L., Palma M. De A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes (TEMs), blood resident monocytes and embryonic macrophages suggests common functions and developmental relationships. Blood 2009, 114:901-914. doi: 10.1182/blood-2009-01-200931. Epub 2009 Apr 21.
49. Carrer A., Moimas S., Zacchigna S., Pattarini L., Zentilin L., Ruozi G., Mano M., Sinigaglia M., Maione F., Serini G., Giraudo E., Bussolino F., Giacca M. Neuropilin-1 identifies a subset of bone marrow gr1- monocytes that can induce tumor vessel normalization and inhibit tumor growth. Cancer. Res. 2012, 72:6371-6381.
50. Fantin A., Vieira J.M., Gestri G., Denti L., Schwarz Q., Prykhozhij S., Peri F., Wilson S.W., Ruhrberg C. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 2010, 116:829-840.
51. Fantin A., Vieira J.M., Plein A., Denti L., Fruttiger M., Pollard J.W., Ruhrberg C. NRP1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis. Blood 2013, 121:2352-2362.
52. Meda C., Molla F., De Pizzol M., Regano D., Maione F., Capano S., Locati M., Mantovani A., Latini R., Bussolino F., Giraudo E. Semaphorin 4A exerts a proangiogenic effect by enhancing vascular endothelial growth factor-A expression in macrophages. J. Immunol. 2012, 188:4081-4092.
53. Ruffell B., Affara N.I., Coussens L.M. Differential macrophage programming in the tumor microenvironment. Trends. Immunol. 2012, 33:119-126.
54. Catalano A., Caprari P., Moretti S., Faronato M., Tamagnone L., Procopio A. Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function. Blood 2006, 107:3321-3329.
55. Yamamoto M., Suzuki K., Okuno T., Ogata T., Takegahara N., Takamatsu H., Mizui M., Taniguchi M., Chedotal A., Suto F., Fujisawa H., Kumanogoh A., Kikutani H. Plexin-A4 negatively regulates T lymphocyte responses. Int. Immunol. 2008, 20:413-420.
56. Hansen W., Hutzler M., Abel S., Alter C., Stockmann C., Kliche S., Albert J., Sparwasser T., Sakaguchi S., Westendorf A.M., Schadendorf D., Buer J., Helfrich I. Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T-cells impairs mouse melanoma growth. J. Exp. Med. 2012, 209:2001-2016.
57. Sarris M., Andersen K.G., Randow F., Mayr L., Betz A.G. Neuropilin-1 expression on regulatory T-cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008, 28:402-413.
58. Solomon B.D., Mueller C., Chae W.J., Alabanza L.M., Bynoe M.S. Neuropilin-1 attenuates autoreactivity in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:2040-2045.
59. Kumanogoh A. [Involvement of immune semaphorins in the immune system]. Tanpakushitsu. Kakusan. Koso. 2002, 47:2254-2260.
60. Watanabe C., Kumanogoh A., Shi W., Suzuki K., Yamada S., Okabe M., Yoshida K., Kikutani H. Enhanced immune responses in transgenic mice expressing a truncated form of the lymphocyte semaphorin CD100. J. Immunol. 2001, 167:4321-4328.
61. Eriksson E.M., Milush J.M., Ho E.L., Batista M.D., Holditch S.J., Keh C.E., Norris P.J., Keating S.M., Deeks S.G., Hunt P.W., Martin J.N., Rosenberg M.G., Hecht F.M., Nixon D.F. Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. Blood 2012, 119:745-755.
62. Mizrahi S., Markel G., Porgador A., Bushkin Y., Mandelboim O. CD100 on NK cells enhance IFNgamma secretion and killing of target cells expressing CD72. PloS one 2007, 2:e818.
63. Czopik A.K., Bynoe M.S., Palm N., Raine C.S., Medzhitov R. Semaphorin 7A is a negative regulator of T cell responses. Immunity 2006, 24:591-600.
64. Suzuki K., Okuno T., Yamamoto M., Pasterkamp R.J., Takegahara N., Takamatsu H., Kitao T., Takagi J., Rennert P.D., Kolodkin A.L., Kumanogoh A., Kikutani H. Semaphorin 7A initiates T-cell-mediated inflammatory responses through alpha1beta1 integrin. Nature 2007, 446:680-684.
65. Holmes S., Downs A.M., Fosberry A., Hayes P.D., Michalovich D., Murdoch P., Moores K., Fox J., Deen K., Pettman G., Wattam T., Lewis C. Sema7A is a potent monocyte stimulator. Scand. J. Immunol. 2002, 56:270-275.
66. Morote-Garcia J.C., Napiwotzky D., Kohler D., Rosenberger P. Endothelial Semaphorin 7A promotes neutrophil migration during hypoxia. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:14146-14151.
67. O'Connor B.P., Eun S.Y., Ye Z., Zozulya A.L., Lich J.D., Moore C.B., Iocca H.A., Roney K.E., Holl E.K., Wu Q.P., van Deventer H.W., Fabry Z., Ting J.P. Semaphorin 6D regulates the late phase of CD4+ T cell primary immune responses. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13015-13020.
68. Kumanogoh A., Shikina T., Suzuki K., Uematsu S., Yukawa K., Kashiwamura S., Tsutsui H., Yamamoto M., Takamatsu H., Ko-Mitamura E.P., Takegahara N., Marukawa S., Ishida I., Morishita H., Prasad D.V., Tamura M., Mizui M., Toyofuku T., Akira S., Takeda K., Okabe M., Kikutani H. Nonredundant roles of Sema4A in the immune system: defective T cell priming and Th1/Th2 regulation in Sema4A-deficient mice. Immunity 2005, 22:305-316.
69. Kumanogoh A., Marukawa S., Suzuki K., Takegahara N., Watanabe C., Ch'ng E., Ishida I., Fujimura H., Sakoda S., Yoshida K., Kikutani H. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature 2002, 419:629-633.
70. Morihana T., Goya S., Mizui M., Yasui T., Prasad D.V., Kumanogoh A., Tamura M., Shikina T., Maeda Y., Iwamoto Y., Inohara H., Kikutani H. An Inhibitory Role for Sema4A in Antigen-Specific Allergic Asthma. J. Clin. Immunol. 2012.